Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.

ABSTRACT: Although ¹⁸ F-fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET) is commonly used for initial staging and therapeutic response evaluation in aggressive lymphomas, its prognostic utility for mantle cell lymphoma (MCL) is controversial. Therefore, we retrospectively evaluated the correlations of interim PET (iPET) and end-of-treatment PET (ePET) response with survival outcomes in 89 consecutive advanced MCL patients treated with frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone). iPET positivity was strongly associated with inferior five-year overall survival (OS) [hazard ratio (HR) 7·84, P < 0·0001] and poor five-year progression-free survival (PFS) (HR 3·34, P < 0·0001). OS and PFS were more favourable in the order ea

SUBMITTER: Jeon YW 

PROVIDER: S-EPMC7155042 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature